Troy Edward Wilson Sells 5,000 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Wilson sold 5,000 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the sale, the director owned 54,750 shares in the company, valued at $498,225. The trade was a 8.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI opened at $9.52 on Friday. The business has a fifty day moving average of $8.74 and a 200-day moving average of $7.67. Puma Biotechnology, Inc. has a twelve month low of $4.37 and a twelve month high of $9.73. The firm has a market cap of $491.42 million, a PE ratio of 18.31 and a beta of 1.24.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to the consensus estimate of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. On average, analysts anticipate that Puma Biotechnology, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Trading of Puma Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kathmere Capital Management LLC increased its stake in Puma Biotechnology by 9.8% in the first quarter. Kathmere Capital Management LLC now owns 29,779 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 2,648 shares in the last quarter. Baron Wealth Management LLC boosted its position in shares of Puma Biotechnology by 8.2% during the first quarter. Baron Wealth Management LLC now owns 38,278 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 2,886 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Puma Biotechnology by 244.5% in the 1st quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 3,066 shares during the period. Legal & General Group Plc acquired a new position in shares of Puma Biotechnology in the 2nd quarter valued at $35,000. Finally, Philadelphia Investment Partners LLC bought a new stake in shares of Puma Biotechnology in the 2nd quarter valued at $65,000. 61.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

PBYI has been the topic of several research analyst reports. TD Cowen increased their price target on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. Weiss Ratings raised Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Finally, Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Puma Biotechnology presently has an average rating of “Hold” and a consensus price target of $6.00.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family.

In the United States, NERLYNX is approved for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab-based therapy.